JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus (Q63813257)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus |
clinical trial |
Statements
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE® (Empagliflozin, 10mg, 25mg, q.d.) in Korean Patients With Type 2 Diabetes Mellitus (English)
0 references
10 August 2016
0 references
30 June 2019
0 references
3,000
0 references
19 year
0 references
110 year
0 references